SCHEMBL2599397

SCHEMBL2599397

CC(=O)NC1=CC(=O)c2cccnc2C1=O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
S100A4 P26447 6/20 1.00
TDP2 O95551 5/20 0.55
G6PD P11413 3/20 0.55
NSD2 O96028 3/20 0.55
CDC25B P30305 3/20 0.55
HKDC1 Q2TB90 2/20 0.55
DUSP3 P51452 1/20 0.55
TGM2 P21980 1/20 0.53
PADI1 Q9ULC6 1/20 0.53
PADI3 Q9ULW8 1/20 0.53
PADI4 Q9UM07 1/20 0.53
PADI2 Q9Y2J8 1/20 0.53
TDP1 Q9NUW8 3/20 0.52
NQO1 P15559 2/20 0.49
MEN1 O00255 3/20 0.48
KMT2A Q03164 3/20 0.48
NPC1 O15118 1/20 0.48
RAB9A P51151 1/20 0.48
THRB P10828 1/20 0.47
BLM P54132 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21882218 0.87 S100A4 (0.77) S100A4TDP2G6PDNSD2CDC25B
SCHEMBL7648238 0.81 S100A4 (0.68) S100A4TDP2G6PDNSD2CDC25B
SCHEMBL8653625 0.78 RAB9A (0.72) S100A4TDP2G6PDCDC25BHKDC1
SCHEMBL21801747 0.78 S100A4 (0.62) S100A4TDP2G6PDNSD2CDC25B
SCHEMBL6294367 0.77 S100A4 (0.62) S100A4TDP2G6PDNSD2CDC25B
SCHEMBL21801779 0.75 S100A4 (0.60) S100A4TDP2G6PDNSD2CDC25B
SCHEMBL8651660 0.75 MAPT (0.78) S100A4TDP2G6PDNSD2CDC25B
SCHEMBL13940474 0.74 S100A4 (0.58) S100A4TDP2G6PDNSD2CDC25B
SCHEMBL21801718 0.74 S100A4 (0.58) S100A4TDP2G6PDHKDC1PADI1
SCHEMBL5925147 0.73 S100A4 (0.58) S100A4TDP2G6PDNSD2CDC25B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130090355-A1 CHEMICAL AGENTS FOR THE PREVENTION OF INHIBITION OR TUMOR METASTASIS ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) 2013-04-11 US claimed
WO-2011146101-A1 CHEMICAL AGENTS FOR THE PREVENTION OR INHIBITION OF TUMOR METASTASIS ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) 2011-11-24 WO claimed
US-20130090355-A1 CHEMICAL AGENTS FOR THE PREVENTION OF INHIBITION OR TUMOR METASTASIS ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) 2013-04-11 US disclosed
US-20130090355-A1 CHEMICAL AGENTS FOR THE PREVENTION OF INHIBITION OR TUMOR METASTASIS ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) 2013-04-11 US disclosed
US-20130090355-A1 CHEMICAL AGENTS FOR THE PREVENTION OF INHIBITION OR TUMOR METASTASIS ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) 2013-04-11 US disclosed
WO-2011146101-A1 CHEMICAL AGENTS FOR THE PREVENTION OR INHIBITION OF TUMOR METASTASIS ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) 2011-11-24 WO disclosed
WO-2011146101-A1 CHEMICAL AGENTS FOR THE PREVENTION OR INHIBITION OF TUMOR METASTASIS ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) 2011-11-24 WO disclosed
US-20060079497-A1 Lavendamycin analogues and methods of synthesizing and using lavendamycin analogues BALL STATE UNIVERSITY 2006-04-13 US disclosed
US-6841555-B2 Lavendamycin analogs, quinoline-5,8-diones and methods of using them BALL STATE UNIVERSITY (US) 2005-01-11 US disclosed
US-20040248922-A1 LAVENDAMYCIN ANALOGS, QUINOLINE-5,8-DIONES AND METHODS OF USING THEM BALL STATE UNIVERSITY 2004-12-09 US disclosed
US-6444684-B1 ANTIBIOTIC AND ANTI-HIV REVERSE TRANSCRIPTASE (HIV-RT) ACTIVITY; TREATING HIV INFECTION AND ALSO WITH AZT; ANTITUMOR BALL STATE UNIVERSITY 2002-09-03 US disclosed
US-6030983-A ANTITUMOR AND -CARCINOGENIC AGENTS; ANTIBIOTICS; BACTERICIDES; VIRICIDES; PARACITICIDES; ENZYME INHIBITORS; POLYMERASES; FARNESYL-PROTEIN TRANSFERASE; RAS PROTEINS BALL STATE UNIVERSITY (US) 2000-02-29 US disclosed
US-5712289-A ANTITUMOR AGENTS, INTERMEDIATES FOR LAVENDAMYCINS BALL STATE UNIVERSITY (US) 1998-01-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130090355-A1 CHEMICAL AGENTS FOR THE PREVENTION OF INHIBITION OR TUMOR METASTASIS S100A4, S100A6, S100A10 S100A4 1/4885TDP2 4122/4885G6PD 1949/4885
US-20040248922-A1 LAVENDAMYCIN ANALOGS, QUINOLINE-5,8-DIONES AND METHODS OF USING THEM LSS, CYP51A1, COX5A S100A4 4553/4885TDP2 2510/4885G6PD 348/4885
US-20060079497-A1 Lavendamycin analogues and methods of synthesizing and using lavendamycin analogues MCL1, LSS, MRPS18A S100A4 4783/4885TDP2 3805/4885G6PD 1712/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.